Ron Kierpa

Chief of Corporate Development at Faraday Pharmaceuticals

Ron Kierpa began serving as Chief of Corporate Development in March 2020. Mr. Kierpa has more than 30 years of pharmaceutical experience, most recently at Merck and Co, where he held a variety of leadership positions in marketing, sales, and market access. From 2017 to 2020, he helped lead the successful market access launch of RENFLEXIS, the first Merck biosimilar. Between 2014 and 2017, Mr. Kierpa was the U.S. Sales Leader for Merck Market Access and led the reorganization of the group, including the successful integration of the Cubist market access team. In addition, he was the U.S. Sales Leader for the Merck Acute Care Salesforce between 2008 and 2010. Mr. Kierpa began his Merck career as a U.S. marketing leader in arthritis and analgesia franchise (VIOXX and ARCOXIA) and progressed to be a leader for the atherosclerosis franchise (ZOCOR). Prior to his time at Merck, Mr. Kierpa held a variety of leadership positions, including U.S. Marketing Group Director at Boehringer Manheim. He received a Bachelor of Science in Business from the University of South Florida.

Links

Previous companies

Merck logo

Org chart